Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

[Vaccines against Herpes zoster: Effectiveness, safety, and cost/benefit ratio].

Ferahta N, Achek I, Dubourg J, Lang PO.

Presse Med. 2016 Feb;45(2):162-76. doi: 10.1016/j.lpm.2015.10.015. Review. French.

PMID:
26724874
2.

Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.

van Lier A, Lugnér A, Opstelten W, Jochemsen P, Wallinga J, Schellevis F, Sanders E, de Melker H, van Boven M.

EBioMedicine. 2015 Aug 8;2(10):1494-9. doi: 10.1016/j.ebiom.2015.08.017.

3.
4.

Vaccination against herpes zoster in developed countries: state of the evidence.

Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M.

Hum Vaccin Immunother. 2013 May;9(5):1177-84. doi: 10.4161/hv.23491. Review.

5.

Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.

Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X.

Hum Vaccin. 2011 Jul;7(7):749-56. doi: 10.4161/hv.7.7.15573.

6.

Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.

Sanford M, Keating GM.

Drugs Aging. 2010 Feb 1;27(2):159-76. doi: 10.2165/10489140-000000000-00000. Review.

PMID:
20104941
7.

Varicella zoster vaccines.

Creed R, Satyaprakash A, Ravanfar P.

Dermatol Ther. 2009 Mar-Apr;22(2):143-9. doi: 10.1111/j.1529-8019.2009.01226.x. Review.

PMID:
19335725
8.

Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ.

Vaccine. 2009 Feb 25;27(9):1454-67. doi: 10.1016/j.vaccine.2008.12.024.

PMID:
19135492
9.

Q: Who should receive the shingles vaccine?

Singh A, Englund K.

Cleve Clin J Med. 2009 Jan;76(1):45-8. doi: 10.3949/ccjm.75a.08046. No abstract available.

10.

Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly.

Opstelten W, van Essen GA, Hak E.

Vaccine. 2009 Jan 7;27(2):192-6. doi: 10.1016/j.vaccine.2008.10.047.

PMID:
18996427
11.

The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.

Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.

Hum Vaccin. 2008 May-Jun;4(3):238-45.

PMID:
18382137
12.

Community and patient values for preventing herpes zoster.

Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA.

Pharmacoeconomics. 2008;26(3):235-49.

PMID:
18282017
13.
14.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Rothberg MB, Virapongse A, Smith KJ.

Clin Infect Dis. 2007 May 15;44(10):1280-8.

15.

Shingles vaccine: effective and costly or cost-effective?

Koplan JP, Harpaz R.

Ann Intern Med. 2006 Sep 5;145(5):386-7. No abstract available.

PMID:
16954362
16.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Hornberger J, Robertus K.

Ann Intern Med. 2006 Sep 5;145(5):317-25.

PMID:
16954357
17.

Summaries for patients. Cost-effectiveness of a vaccine to prevent herpes zoster (shingles) in older adults.

[No authors listed]

Ann Intern Med. 2006 Sep 5;145(5):I14. No abstract available.

PMID:
16954354
18.

Varicella-zoster virus vaccine--grown-ups need it, too.

Gilden DH.

N Engl J Med. 2005 Jun 2;352(22):2344-6. No abstract available.

PMID:
15930426
19.

Cost containment analysis of childhood vaccination against varicella in Israel.

Ginsberg GM, Somekh E.

J Infect. 2004 Feb;48(2):119-33. Review.

PMID:
14720487
20.

A cost-effectiveness model for analyzing two varicella vaccination strategies.

Gayman J.

Am J Health Syst Pharm. 1998 Dec 15;55(24 Suppl 4):S4-8.

PMID:
9872686
Items per page

Supplemental Content

Loading ...
Support Center